Does our current understanding of the molecular basis of immune tolerance predict new therapies for autoimmune disease?

Nature Clinical Practice Rheumatology

Volumn 2, Issue 9, 2006, Pages 491-499

  Tarner, Ingo H ^a   Fathman, C Garrison ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD40 LIGAND MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD28; OKT 4; RAPAMYCIN; RITUXIMAB; TGN 1412; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN SPECIFICITY; APOPTOSIS; AUTOIMMUNE DISEASE; CHIMERA; CLINICAL PROTOCOL; CLINICAL TRIAL; CLONAL ANERGY; DENDRITIC CELL; GENE IDENTIFICATION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LYMPHOCYTE DEPLETION; LYMPHOCYTOPENIA; MOLECULAR DYNAMICS; NONHUMAN; NONMYELOABLATIVE CONDITIONING; PREDICTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; THROMBOSIS;

AUTOIMMUNE DISEASES; CLONAL ANERGY; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY;

EID: 33748425418     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0272     Document Type: Review

References (93)

1. Steinman RM and Nussenzweig MC (2002) Avoiding horror autotoxicus: The importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 99: 351-358
2. Knechtle SJ and Burlingham WJ (2004) Metastable tolerance in nonhuman primates and humans. Transplantation 77: 936-939
3. Choy EHS et al. (1998) Monoclonal antibody therapy in rheumatoid arthritis. Br J Rheumatol 37: 484-490
4. Hoyer BF et al. (2005) Long-lived plasma cells and their contribution to autoimmunity. Ann NY Acad Sci 1050: 124-133
5. Choy EH et al. (1992) Treatment of rheumatoid arthritis with single dose or weekly pulses of chimeric anti-CD4 monoclonal antibody. Scand J Immunol 36: 291-298
6. Edwards JC et al. (2004) Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350: 2572-2581
7. Hawiger D et al. (2001) Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194: 769-779
8. Zhang HG et al. (1999) Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells. J Immunol 162: 1423-1430
9. Liu Z et al. (2003) CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis. J Clin Invest 112: 1332-1341
10. Graham KL et al. (2004) High-throughput methods for measuring autoantibodies in systemic lupus erythematosus and other autoimmune diseases. Autoimmunity 37: 269-272
11. Hueber W et al. (2005) Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum 52: 2645-2655
12. Alderuccio F et al. (2003) Stem cells engineered to express self-antigen to treat autoimmunitiy. Trends Immunol 24: 176-180
13. Sykes M and Nikolic B (2005) Treatment of severe autoimmune disease by stem-cell transplantation. Nature 435: 620-627
14. Burt RK et al. (2004) Induction of remission of severe and refractory rheumatoid arthritis by allogeneic mixed chimerism. Arthritis Rheum 50: 2466-2470
15. Khorshid O et al. (2004) Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus. J Rheumatol 31: 2513-2516
16. Wekerle T et al. (2001) Peripheral deletion after bone marrow transplantation with costimulatory blockade has features of both activation-induced cell death and passive cell death. J Immunol 166: 2311-2316
17. + T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. J Exp Med 191: 651-660.
18. Wekerle T et al. (1999) Anti-CD154 or CTLA4Ig obviates the need for thymic irradiation in a non-myeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and tolerance. Transplantation 68: 1348-1355
19. Nikolic B et al. (2004) Mixed hematopoietic chimerism allows cure of autoimmune diabetes through allogeneic tolerance and reversal of autoimmunity. Diabetes 53: 376-383
20. Wekerle T et al. (2000) Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 6: 464-469
21. Kawai T et al. (2000) Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 6: 114
22. Kremer JM et al. (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349: 1907-1915
23. Larsen CP et al. (2005) Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 5: 443-453
24. Adams AB et al. (2005) Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol 174: 542-550
25. Kirk AD et al. (2001) The role of CD154 in organ transplant rejection and acceptance. Philos Trans R Soc Lond B Biol Sci 356: 691-702
26. + T cells, precluding a role for sustained regulation. Eur J Immunol 35: 2679-2690
27. Westhuis G et al. (2005) Long-term mixed chimerism after immunologic conditioning and MHC-mismatched stem-cell transplantation is dependent on NK-cell tolerance. Blood 106: 2215-2220
28. Schwartz RH (2003) T cell anergy. Annu Rev Immunol 21: 305-334
29. + T cells facilitate the induction of T cell anergy. J Immunol 167: 4271-4275
30. Gauld SB et al. (2005) Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling. Nat Immunol 6: 1160-1167
31. Wells AD et al. (2001) Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. J Clin Invest 108: 895-903
32. Lechler R et al. (2001) The contributions of T-cell anergy to peripheral tolerance. Immunology 103: 262-269
33. Quill H and Schwartz RH (1987) Stimulation of normal inducer T cell clones with antigen presented by purified la molecules in planar lipid memebranes: Specific induction of a long-lived state of proliferative unresponsiveness. J Immunol 138: 3704-3712
34. Jenkins MK et al. (1987) Molecular events in the induction of a nonresponsive state in interleukin 2-producing helper T-lymphocyte clones. Proc Natl Acad Sci USA 84: 5409-5413
35. Kang SM et al. (1992) Transactivation by AP-1 is a molecular target of T cell clonal anergy. Science 257: 1134-1138
36. + T cells. J Immunol 151: 2355-2367
37. Mondino A et al. (1996) Defective transcription of the IL-2 gene is associated with impaired expression of c-Fos, FosB, and JunB in anergic T helper 1 cells. J Immunol 157: 2048-2057
38. + T cells. Science 271: 1272-1276
39. + T cells. Science 271: 1276-1278
40. Becker JC et al. (1995) Negative transcriptional regulation in anergic T cells. Proc Natl Acad Sci USA 92: 2375-2378
41. Powell JD et al. (1998) Molecular regulation of interleukin-2 expression by CD28 co-stimulation and anergy. Immunol Rev 165: 287-300
42. Korthauer U et al. (2000) Anergic T lymphocytes selectively express an integrin regulatory protein of the cytohesin family. J Immunol 164: 308-318
43. Mueller DL (2004) E3 ubiquitin ligases as T cell anergy factors. Nat Immunol 5: 883-890
44. Jeon MS et al. (2004) Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity 21: 167-177
45. + T cells. Immunity 18: 535-547
46. Heissmeyer V et al. (2004) Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins. Nat Immunol 5: 255-265
47. Hershko A and Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67: 425-479
48. Pickart CM (2000) Ubiquitin in chains. Trends Biochem Sci 25: 544-558
49. Pickart CM (2001) Mechanisms underlying ubiquitination. Annu Rev Biochem 70: 503-533
50. Wang HY et al. (2001) Cbl promotes ubiquitination of the T cell receptor ζ through an adaptor function of Zap-70. J Biol Chem 276: 26004-26011
51. Naramura M et al. (2002) c-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation. Nat Immunol 3: 1192-1199
52. Fang D and Liu YC (2001) Proteolysis-independent regulation of phosphatidylinositol 3-kinase by Cbl-b-mediated ubiquitination in T cells. Nat Immunol 2: 870-875
53. Bachmaier K et al. (2000) Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 403: 211-216
54. Chiang YJ et al. (2000) Cbl-b regulates the CD28 dependence of T cell activation. Nature 403: 216-220
55. Krawczyk C et al. (2000) Cbl-b is a negative regulator of receptor clustering and raft aggregation in T cells. Immunity 13: 463-473
56. Zhang J et al. (2002) Cutting edge: Regulation of T cell activation threshold by CD28 costimulation through targeting Cbl-b for ubiquitination. J Immunol 169: 2236-2240
57. Seroogy CM et al. (2004) The gene related to anergy in lymphocytes, an E3 ubiquitin ligase, is necessary for anergy induction in CD4 T cells. J Immunol 173: 79-85
58. Soares L et al. (2004) Two isoforms of otubain 1 regulate T cell anergy via GRAIL. Nat Immunol 5: 45-54
59. + naturally anergic and suppressive T cells: Induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 10: 1969-1980
60. + naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 162: 5317-5326
61. + regulatory T cells in the steady state. J Exp Med 198: 737-746
62. + suppressor T cells in vivo. Nat Immunol 3: 33-41
63. Klein L et al. (2003) In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci USA 100: 8886-8891
64. H2-inducing cytokines. J Exp Med 195: 603-616
65. + regulatory T cells. J Immunol 172: 5986-5993
66. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 198: 1875-1886
67. Tang Q et al. (2004) In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 199: 1455-1465
68. Rao PE et al. (2005) Differentiation and expansion of T cells with regulatory function from human peripheral lymphocytes by stimulation in the presence of TGF-β. J Immunol 174: 1446-1455
69. + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192: 1213-1222
70. Sato K et al. (2003) Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood 101: 3581-3589
71. + T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med 199: 1467-1477
72. + T cells by human mature autologous dendritic cells. Eur J Immunol 34: 762-772
73. Wakkach A et al. (2001) Differentiation of regulatory T cells is induced by CD2 costimulation. J Immunol 167: 3107-3113
74. Sundstedt A et al. (2003) Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo. J Immunol 170: 1240-1248
75. Apostolou I and von Boehmer H (2004) In vivo instruction of suppressor commitment in naive T cells. J Exp Med 199: 1401-1408
76. + precursors in a thymus-independent process. J Immunol 172: 923-928
77. + regulatory T cells in the periphery of T cell receptor transgenic mice tolerized to transplants. J Immunol 172: 6003-6010
78. Herold KC et al. (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346: 1692-1698
79. Hori S et al. (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061
80. + regulatory T cells. Nat Immunol 4: 330-336
81. + T regulatory cells. Nat Immunol 4: 337-342
82. Roncarolo MG et al. (2001) Type 1 T regulatory cells. Immunol Rev 182: 68-79
83. H3 regulatory cells. Immunol Rev 182: 207-214
84. Kretschmer K et al. (2005) Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 6: 1219-1227
85. Assemann C et al. (1999) An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 190: 995-1003
86. Hare M et al. (2001) IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 166: 3789-3796
87. R cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med 197: 111-119
88. + regulatory T cells is mediated by cell surface-bound transforming growth factor β. J Exp Med 194: 629-644
89. Huang CT et al. (2004) Role of LAG-3 in regulatory T cells. Immunity 21: 503-513
90. + T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol 172: 4100-4110
91. Paust S et al. (2004) Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc Natl Acad Sci USA 101: 10398-10403
92. + antigen-specific regulatory T cells. Proc Natl Acad Sci USA 101 (Suppl 2): 14622-14626
93. British Medicines and Healthcare products Regulatory Agency (online 25 May 2006) Press release: Final report on TGN1412 clinical trial. [http://www.mhra.gov.uk/home/ idcplg?ldcService=SS_GET_PAGE&useSecondary=true&ssDocName= CON2023822&ssTargetNodeld=389 (accessed 14 July 2006)